Novel strategies based on our knowledge concerning the involvement of FICZ in intestinal immunity may lead to more effective control of this disease, as well as of other autoimmune diseases, since FICZ can activate tolerogenic T cells (reviewed in [2]), in addition to the stimulation of systemic IL-22 signaling described in this review. The gene discussed is IL22; the disease is autoimmune disease.